| 105 HIGH RESPONSE RATE FOR AZACITIDINE-LENALIDOMIDE (VI-LEN) COMBINATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)-VILEN-01 PROTOCOL UPDATE M Mittelman, K Filanovsky, Y Ofran, P Raanani, A Braester, N Goldshmidt, ... Leukemia Research, S54, 2015 | | 2015 |
| 185 Severe thrombocytopenia but not neutropenia predicts infection complications during azacitidine therapy in high risk MDS patients Y Ofran, DJ Eldad, N Haddad, N Benyamini, R Hoffman, T Zuckerman Leukemia Research, S73, 2011 | | 2011 |
| 194 ACUTE FIBRINOUS ORGANIZING PNEUMONIA AS A PARA NEOPLASTIC PHENOMENA IN A HIGH RISK MYELODYSPLASTIC SYNDROME PATIENT RESOLVING WITH AZACITIDINE THERAPY Y Ofran, M Yigla Leukemia Research, S97, 2015 | | 2015 |
| 2: Identification of Human Minor Histocompatibilty Antigens (mHA) by Combining Bioinformatic Prediction of Peptide Epitopes With Validation of T Cell Reactivity in Patient … Y Ofran, V Brusic, RJ Soiffer, JH Antin, J Ritz Biology of Blood and Marrow Transplantation 14 (2), 1, 2008 | 9 | 2008 |
| 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood 138 (26), 2753-2767, 2021 | 38 | 2021 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 402 | 2021 |
| A chemotherapy-free regimen for Ph+ acute lymphoblastic leukemia: are we there yet? Y Ofran | | |
| A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet? Y Ofran haematologica 106 (7), 1781, 2021 | | 2021 |
| A Doctor's Duties in Terror-Struck Communities Y Ofran AMA Journal of Ethics 6 (5), 248-250, 2004 | | 2004 |
| A phase 1 study of Flotetuzumab, a CD123 x CD3 DART® protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia AH Wei, CY Fong, P Montesinos, M Calbacho, JS Gil, JP De Oteyza, ... Blood 134, 2662, 2019 | 12 | 2019 |
| A pneumococcal conjugate vaccine and acute otitis media. EI Cantekin The New England journal of medicine 344 (22), 1719-1720, 2001 | 8 | 2001 |
| A PROSPECTIVE COMPARATIVE STUDY OF EXTRACORPOREAL PHOTOPHERESIS PERFORMED USING THE OPEN-LOOP COBE (R) SPECTRA OR SPECTRA OPTIA (R) SYSTEM VERSUS THE CLOSED-LOOP THERAKOS (TM … EJ Dann, E Sabbag, T Mashiach, T Stravets, A Badian, S Finkelbaum, ... BONE MARROW TRANSPLANTATION 49, S282-S282, 2014 | | 2014 |
| A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT … AE Dezern, G Marconi, D Deeren, M Diez Campelo, M Lübbert, ... Journal of Clinical Oncology 40 (16_suppl), TPS7075-TPS7075, 2022 | 3 | 2022 |
| A unique peripheral blood karyotype characterized by multiple complex chromosomal translocations is caused by homozygosity for the CHEK2 p. Gly167Arg variant T Paperna, N Sharon-Shwartzman, A Kurolap, Y Goldberg, N Moustafa, ... MOLECULAR CYTOGENETICS 12, 2019 | | 2019 |
| Activated kinases in ALL: time to act Y Ofran Blood, The Journal of the American Society of Hematology 129 (25), 3280-3282, 2017 | 2 | 2017 |
| Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Heuser, Y Ofran, N Boissel, SB Mauri, C Craddock, J Janssen, ... Annals of Oncology 31 (6), 697-712, 2020 | 241 | 2020 |
| Acute myeloid leukemia in adolescents and young adults: challenging aspects JM Rowe, Y Ofran Acta haematologica 132 (3-4), 292-297, 2014 | 36 | 2014 |
| Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study T Berger, Y Moshe, S Yaari, I Hellmann, A Aviram, P Raanani, R Ram, ... Blood 132 (Supplement 1), 4005-4005, 2018 | | 2018 |
| Administration of all-trans retinoic acid (ATRA) to newly diagnosed patients (pts) with acute promyelocytic leukemia (APL) is delayed even at experienced centers and associated … JK Altman, A Rademaker, E Cull, BB Weitner, Y Ofran, TL Rosenblat, ... Blood 118 (21), 942, 2011 | 5 | 2011 |
| Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death JK Altman, A Rademaker, E Cull, BB Weitner, Y Ofran, TL Rosenblat, ... Leukemia research 37 (9), 1004-1009, 2013 | 123 | 2013 |
